BRANMOOR
THURSDAY · 14 MAY 2026

Azithromycin Dihydrate

Injection · trading as Zithromax

To Be Discontinued Active (discontinuing) — Day 114 FDA record updated

Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.

FDA shortage record

Substance
Azithromycin Dihydrate
Brand name
Zithromax
Manufacturers / suppliers
  • Pfizer Laboratories Div Pfizer Inc
  • Pfizer Inc.
2 known suppliers in current FDA data
Dosage form
Injection
Presentation
Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)
Route(s)
INTRAVENOUS
Therapeutic category
Anti-Infective
Package NDC
0069-3150-83
Initially posted
01/20/2026
Days on shortage list
114
Discontinued
01/20/2026
Current FDA status
To Be Discontinued
Shortage entries (current dataset)
2 records for Azithromycin Dihydrate

Why this shortage matters

Anti-infective drugs — antibiotics, antivirals, and antifungals — treat bacterial, viral, and fungal infections. A shortage can delay care for serious hospital-acquired or opportunistic infections, where drug choice and timing directly affect patient outcomes.

FDA therapeutic class: Anti-Infective

Reason and context

Discontinuation of the manufacture of the drug.

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 844-646-4398.

If you're affected by this shortage

  • Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
  • Ask your pharmacy to check supply across multiple wholesalers and other branches.
  • Check current pharmacy pricing and availability via GoodRx (affiliate link).
  • Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.